EXPLORE!

IDSA Updates Guidelines for Treatment of COVID-19

  959 Views

eMediNexus    20 March 2021

The Infectious Diseases Society of America (IDSA) continues to evaluate the available and potential treatment options for the treatment of COVID-19 as new evidence continues to emerge.

A new recommendation in IDSA guidelines is the use of combination of monoclonal antibodies bamlanivimab and etesevimab to treat outpatients with mild-to-moderate disease at risk of progression to severe COVID-19. The society updated its recommendation for tocilizumab, suggesting the use of this drug in hospitalized patients with elevated blood markers even after treatment with steroids, thus being at risk for progression to severe COVID-19. The guideline suggests against the use of ivermectin outside of a clinical trial for hospitalized patients as well as outpatients… (Medscape)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.